Keros Therapeutics (NASDAQ:KROS) Given New $111.00 Price Target at Wells Fargo & Company

Keros Therapeutics (NASDAQ:KROS) had its price objective increased by Wells Fargo & Company from $88.00 to $111.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock.

KROS has been the topic of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Wedbush reissued an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating for the company. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $95.22.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $18.43 on Wednesday. Keros Therapeutics has a one year low of $15.67 and a one year high of $73.00. The business has a fifty day moving average of $59.95 and a two-hundred day moving average of $52.83.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.33) earnings per share. On average, analysts expect that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors have recently bought and sold shares of the stock. KBC Group NV boosted its holdings in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of Keros Therapeutics in the 3rd quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics in the second quarter valued at $128,000. Finally, LMR Partners LLP purchased a new stake in Keros Therapeutics during the third quarter valued at about $213,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.